Antiviral Therapy
Overview
Authors
Affiliations
The current status of antiviral therapy is reviewed, including discussion of older approaches together with more recently developed chemotherapy. Following the introduction dealing with pathophysiological aspects of virus disease, the different approaches to antiviral therapy are presented. The reasons for the slow progress in antiviral therapy are discussed. These include: 1. the necessity of intracellular penetration of drugs acting on viral replication; 2. the severe toxicity of most antiviral drugs; 3. the narrow antiviral spectrum of most of these agents; 4. the difficulty of making a rapid etiological diagnosis in view of the necessity of starting (specific?) treatment early in the course of the disease; 5. the difficult evaluation of beneficial as compared with deleterious effects of antiviral therapy. After a detailed review of clinically tested substances, including immunoglobulins, synthetic antiviral drugs (amantadine, nucleoside analogs, thiosemicarbazones and photodynamic dyes) and interferon, a guide concerning indications and application of specific antiviral therapy is presented. Although at present there are few indications, clinicians should be aware of the (present and future) possibilities of antiviral therapy.
Antivirals against animal viruses.
Villa T, Feijoo-Siota L, Rama J, Ageitos J Biochem Pharmacol. 2016; 133:97-116.
PMID: 27697545 PMC: 7092833. DOI: 10.1016/j.bcp.2016.09.029.
Antiviral therapy: a perspective.
Shahidi Bonjar A Drug Des Devel Ther. 2016; 10:541-6.
PMID: 26893542 PMC: 4745851. DOI: 10.2147/DDDT.S83037.
Henderson E, LONG W, Ribecky R Antimicrob Agents Chemother. 1979; 15(1):101-10.
PMID: 218497 PMC: 352607. DOI: 10.1128/AAC.15.1.101.
Antiviral agents: action and clinical use.
Chang T, Snydman D Drugs. 1979; 18(5):354-76.
PMID: 92398 DOI: 10.2165/00003495-197918050-00002.